Rimonabant has been called the anti-marijuana.

A attendant clinical legal proceeding tested whether rimonabant for smoke cessation. The 10-week legal proceeding enrolled nearly 800 men and women who smoked an ratio of 23 cigarettes a day before the subject field began. The goal was no vaporisation for at least four consecutive weeks.
Of those who completed the thoughtfulness, 36.2% of those who received a 20-mg dose of rimonabant quit vapor compared with about one common fraction of those who received medicament.
None of these smokers were obese. But participants in the medication grouping gained 6.6 pounds, while those in the rimonabant radical gained only 1.5 pounds.
A one-year addendum of the experimentation is underway in the U.S. and EEC.
Rimonabant has been called the anti-marijuana. It blocks the CB-1 cannabinoid receptors, which are found on brass and fat cells.